-- Target diseases for this collaboration are Diffuse Large Cell Lymphoma,
Transformed Follicular Lymphoma, and Chronic Lymphocytic Leukemia
-- Collaboration to develop microRNA-based diagnostics test, early
detection and prognosis. -- 43,000 people will be diagnosed with these types of cancers in 2007 in
the US alone(1) -- MicroRNAs hold significant potential as highly sensitive and specific
biomarkers for hematological cancers -- Collaboration also will seek to identify microRNA (miRNA) targets for
REHOVOT, Israel and NEW YORK, Dec. 13 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (Nasdaq: ROSG) and Columbia University Medical Center announced today they will collaborate to develop microRNA-based diagnostic tests, early detection as well as prognosis, for Diffuse Large Cell Lymphoma, Transformed Follicular Lymphoma, and for Chronic Lymphocytic Leukemia. Three types of Non- Hodgkin Lymphoma (NHL).
"We are constantly expanding our pipeline with new diagnostic and therapeutic programs, both cancer and non-cancer related, in order to maximize our leading position in microRNA intellectual property and proprietary technologies", noted Amir Avniel, President and CEO of Rosetta Genomics. "We are very excited to be collaborating with a leading research institution such as Columbia University Medical Center, and hope more collaboration will follow."
Combining Rosetta Genomics know-how and proprietary technologies with
Columbia University Medical Center's expertise in cancer, researchers will
screen for microRNAs that may be used as potential biomarkers and drug
targets for t
|SOURCE Rosetta Genomics|
Copyright©2007 PR Newswire.
All rights reserved